Show simple item record

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial

dc.contributor.authorPaz-Ares, L
dc.contributor.authorSpira, A
dc.contributor.authorRaben, D
dc.contributor.authorPlanchard, D
dc.contributor.authorCho, BC
dc.contributor.authorOzguroglu, M
dc.contributor.authorDaniel, D
dc.contributor.authorVillegas, A
dc.contributor.authorVicente, D
dc.contributor.authorHui, R
dc.contributor.authorMurakami, S
dc.contributor.authorSpigel, D
dc.contributor.authorSenan, S
dc.contributor.authorLanger, CJ
dc.contributor.authorBoothman, AM
dc.contributor.authorBroadhurst, H
dc.contributor.authorWadsworth, C
dc.contributor.authorDennis, PA
dc.contributor.authorAntonia, SJ
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2020-04-22T07:25:08Z
dc.date.available2020-04-22T07:25:08Z
dc.date.issued2020en
dc.identifier.citationPaz-Ares L, Dziadziuszko R, Drilon A, John T, Krebs M, Demetri G, et al. Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors or ROS1-Positive NSCLC with CNS Metastases. Oncology Research and Treatment. 2020;43:235-en
dc.identifier.pmid32209338en
dc.identifier.doi10.1016/j.annonc.2020.03.287en
dc.identifier.urihttp://hdl.handle.net/10541/622912
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2020.03.287en
dc.titleOutcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trialen
dc.typeArticleen
dc.contributor.departmentHospital Universitario 12 de Octubre, Lung Cancer Unit CNIO-H12o, CiberOnc and Universidad Complutense, Madrid, Spainen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record